Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9153454 | 0.84 | GRIN2D (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7779798 | 0.82 | GRIN2D (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10922033 | 0.79 | GAA (0.48) | GAAALDH1A1 | |
| SCHEMBL28271960 | 0.79 | GAA (0.35) | GAAALDH1A1 | |
| SCHEMBL8525834 | 0.79 | GAA (0.35) | GAAALDH1A1 | |
| SCHEMBL25248829 | 0.78 | CD44 (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8873189 | 0.76 | GAA (0.36) | GAAALDH1A1 | |
| SCHEMBL25244744 | 0.75 | CD44 (0.46) | GAAALDH1A1 | |
| SCHEMBL6471851 | 0.75 | PTK2 (0.41) | GAAALDH1A1 | |
| SCHEMBL998262 | 0.75 | ALDH1A1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9072796-B2 | Method for preparing deuterated diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2015-07-07 | — | — | US | disclosed |
| US-20140088311-A1 | METHOD FOR PREPARING DEUTERATED DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-03-27 | — | — | US | disclosed |
| US-8618306-B2 | Method for preparing deuterated diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-12-31 | — | — | US | disclosed |
| US-20130060044-A1 | METHOD FOR PREPARING DEUTERATED DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-03-07 | — | — | US | disclosed |
| EP-2548867-A1 | METHOD FOR PREPARING DEUTERATED DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2013-01-23 | — | — | EP | disclosed |
| US-20130012548-A1 | DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-01-10 | — | — | US | disclosed |
| US-7750047-B2 | Modulators (inhibitors/activators) of histone acetyltransferases | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2010-07-06 | — | — | US | disclosed |
| US-20090076155-A1 | MODULATORS (INHIBITORS/ACTIVATORS) OF HISTONE ACETYLTRANSFERASES | KUNDU TAPAS KUMAR | 2009-03-19 | — | — | US | disclosed |
| US-7332629-B2 | Modulators (inhibitors/activators) of histone acetyltransferases | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2008-02-19 | — | — | US | disclosed |
| US-20060167107-A1 | Modulators (inhibitors/ activators) of histone acetyltransferases | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2006-07-27 | — | — | US | disclosed |
| EP-1590318-A2 | MODULATORS (INHIBITORS/ACTIVATORS) OF HISTONE ACETYLTRANSFERASES | Jawaharlal Nehru Centre For Advanced Scientific Research (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004053140-A2 | MODULATORS (INHIBITORS/ACTIVATORS) OF HISTONE ACETYLTRANSFERASES | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167107-A1 | Modulators (inhibitors/ activators) of histone acetyltransferases | EP300, HDAC1, KAT2A | GRIN2D 4481/4885GRIN3B 3218/4885GRIN1 2646/4885 |
| US-20140088311-A1 | METHOD FOR PREPARING DEUTERATED DIPHENYLUREA | NMUR1, NMUR2, NUDT1 | GRIN2D 847/4885GRIN3B 1916/4885GRIN1 432/4885 |
| US-20130012548-A1 | DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | PPARD, HDHD5, SCD | GRIN2D 3779/4885GRIN3B 4261/4885GRIN1 4662/4885 |
| US-20090076155-A1 | MODULATORS (INHIBITORS/ACTIVATORS) OF HISTONE ACETYLTRANSFERASES | KAT2A, HDAC5, HAT1 | GRIN2D 4563/4885GRIN3B 3822/4885GRIN1 2710/4885 |
| US-20130060044-A1 | METHOD FOR PREPARING DEUTERATED DIPHENYLUREA | NMUR1, NMUR2, NUDT1 | GRIN2D 847/4885GRIN3B 1916/4885GRIN1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.